Sanofi's SERD Candidate Founders In Advanced Breast Cancer
But Hope Remains For Earlier Setting
Executive Summary
The French major’s amcenestrant has missed its primary endpoint in a Phase II study of advanced breast cancer patients but could still have potential in earlier adjuvant disease.
You may also be interested in...
AstraZeneca Cancer Pipeline Boost With AKT And SERD Successes
A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.
Dupixent Drives Sanofi Growth Again Amid Pipeline Renewal
The major’s atopic dermatitis blockbuster made more than €1.6bn this quarter, but the firm’s R&D costs are rising as it attempts to add some fresh blood to its stagnating pipeline.
Roche's SERD Setback Means Menarini Retains An Edge
Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.